Vergoeding 2018-2022 voor ATC-subgroep J05AF : Nucleoside en nucleotide reverse-transcriptaseremmers
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| J05AF01 Zidovudine (Retrovir ®) | 32.785 | 19.823 | 13.729 | 18.596 | 16.763 |
| J05AF02 Didanosine | 648 | . | . | . | . |
| J05AF05 Lamivudine (Epivir ®) | 529.190 | 424.470 | 301.640 | 229.880 | 165.600 |
| J05AF06 Abacavir (Ziagen ®) | 505.680 | 385.420 | 302.520 | 257.700 | 215.950 |
| J05AF07 Tenofovirdisoproxil (Viread ®) | 2.534.500 | 994.490 | 876.800 | 676.300 | 634.570 |
| J05AF08 Adefovir (Hepsera ®) | 340.800 | 246.130 | 190.890 | 159.190 | 126.490 |
| J05AF09 Emtricitabine (Emtriva ®) | 57.383 | 50.287 | 52.636 | 44.421 | 40.514 |
| J05AF10 Entecavir (Baraclude ®) | 3.425.200 | 1.484.400 | 1.641.200 | 1.326.500 | 1.441.800 |
| J05AF11 Telbivudine | 24.060 | 20.327 | 2.504 | . | . |
| J05AF13 Tenofoviralafenamide (Vemlidy ®) | 519.990 | 1.101.300 | 1.595.100 | 1.790.200 | 1.959.800 |
| Totaal | 7.970.236 | 4.726.647 | 4.977.019 | 4.502.787 | 4.601.487 |